Germany-based ITM Isotope Technologies Munich SE received a Complete Response Letter (CRL) from the US FDA on August 7, 2026, for its New Drug Application (NDA) for ¹⁷⁷Lu-edotreotide (ITM-11), a targeted radiotherapeutic under review for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The agency stated it cannot approve the NDA in its present form, delaying what had been a PDUFA goal date of August 28, 2026.
The FDA cited Chemistry, Manufacturing and Controls (CMC) deficiencies and unresolved conditions at a third-party commercial manufacturing facility as the sole basis for the CRL. The agency did not identify concerns with the clinical or nonclinical data package, the safety profile of ITM-11, or request any new clinical or nonclinical studies. Resolution of the facility inspection-related conditions is required before approval can proceed. The source and scope of the manufacturing deficiencies have not been publicly specified by ITM.
The CRL arrives one month after Phase III COMPETE trial results were published in The Lancet, reporting that ¹⁷⁷Lu-edotreotide demonstrated statistically significant improvement in progression-free survival versus everolimus (23.9 versus 14.1 months; p=0.022; HR 0.67). The clinical data package therefore remains intact. The setback follows a late-June CRL for Lantheus Holdings' separate radiopharmaceutical NDA for LNTH-2501 (gallium Ga 68 edotreotide), which likewise cited unresolved conditions at a third-party manufacturing facility without identifying safety or efficacy concerns. The two decisions highlight manufacturing and facility compliance as an increasingly visible regulatory risk for radiopharmaceutical developers.
¹⁷⁷Lu-edotreotide is a lutetium-177-labeled somatostatin analogue that delivers targeted radiation to somatostatin receptor-positive tumor cells. GEP-NETs are rare tumors of the gastrointestinal tract and pancreas; treatment options remain limited following progression on first-line somatostatin analog therapy. The most directly comparable approved radioligand therapy is Novartis' Lutathera (lutetium Lu 177 dotatate), another somatostatin receptor-targeted radiotherapeutic for GEP-NETs.